# AlTi Global, Inc.: financial statements, quarterly

ALTI · Nasdaq · CIK 1838615 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alti.md) · [Financials](/companies/alti/financials.md) · [Filings](/companies/alti/filings.md) · [Insiders](/companies/alti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [48.2](/filings/0001628280-24-046969.md) | [63.6 d](/filings/0001628280-26-022450.md) | [50.8](/filings/0001628280-25-024649.md) | [49.5](/filings/0001628280-25-039531.md) | [51.8](/filings/0001628280-25-051776.md) | [51.5 d](/filings/0001628280-26-022450.md) | [57.1](/filings/0001628280-26-033621.md) | [52.4](/filings/0001628280-26-055274.md) | [57.2](/filings/0001628280-25-051776.md) | [88.3 d](/filings/0001628280-26-022450.md) | [73.1](/filings/0001628280-26-033621.md) | [58.0](/filings/0001628280-26-055274.md) |
| Operating income | $m | [(25.1)](/filings/0001628280-24-046969.md) | [33.3 d](/filings/0001628280-26-022450.md) | [(14.7)](/filings/0001628280-25-024649.md) | [(15.0)](/filings/0001628280-25-039531.md) | [(9.5)](/filings/0001628280-25-051776.md) | [(33.5) d](/filings/0001628280-26-022450.md) | [(8.4)](/filings/0001628280-26-033621.md) | [(25.6)](/filings/0001628280-26-055274.md) | [(28.5)](/filings/0001628280-25-051776.md) | [(11.5) d](/filings/0001628280-26-022450.md) | [(10.7)](/filings/0001628280-26-033621.md) | [(10.9)](/filings/0001628280-26-055274.md) |
| Interest expense | $m | [3.7](/filings/0001628280-24-046969.md) | [4.4 d](/filings/0001628280-26-022450.md) | [4.8](/filings/0001628280-24-022638.md) | [4.9](/filings/0001628280-25-039531.md) | [5.2](/filings/0001628280-25-051776.md) | [7.3 d](/filings/0001628280-26-022450.md) | [0.2](/filings/0001628280-26-033621.md) | [0.0](/filings/0001628280-26-055274.md) | [0.1](/filings/0001628280-25-051776.md) | [0.1 d](/filings/0001628280-26-022450.md) | [0.1](/filings/0001628280-26-033621.md) | [0.4](/filings/0001628280-26-055274.md) |
| Income tax | $m | [(1.8)](/filings/0001628280-24-046969.md) | [12.1 d](/filings/0001628280-26-022450.md) | [0.4](/filings/0001628280-25-024649.md) | [(0.8)](/filings/0001628280-25-039531.md) | [(9.5)](/filings/0001628280-25-051776.md) | [(10.9) d](/filings/0001628280-26-022450.md) | [(1.6)](/filings/0001628280-26-033621.md) | [(4.8)](/filings/0001628280-26-055274.md) | [30.1](/filings/0001628280-25-051776.md) | [(5.1) d](/filings/0001628280-26-022450.md) | [(0.0)](/filings/0001628280-26-033621.md) | [0.1](/filings/0001628280-26-055274.md) |
| Net income | $m | [(89.7)](/filings/0001628280-24-046969.md) | [(49.9) d](/filings/0001628280-26-022450.md) | [29.7](/filings/0001628280-25-024649.md) | [(6.4)](/filings/0001628280-25-039531.md) | [(72.5)](/filings/0001628280-25-051776.md) | [(53.8) d](/filings/0001628280-26-022450.md) | [1.9](/filings/0001628280-26-033621.md) | [(24.4)](/filings/0001628280-26-055274.md) | [(84.1)](/filings/0001628280-25-051776.md) | [(13.1) d](/filings/0001628280-26-022450.md) | [7.7](/filings/0001628280-26-033621.md) | [(23.5)](/filings/0001628280-26-055274.md) |
| Diluted EPS | $ per share | [(1.41)](/filings/0001628280-24-046969.md) | not reported | [0.18](/filings/0001628280-25-024649.md) | [(0.18)](/filings/0001628280-25-039531.md) | [(0.88)](/filings/0001628280-24-046969.md) | not reported | [(0.04)](/filings/0001628280-25-024649.md) | [(0.33)](/filings/0001628280-25-039531.md) | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(1.41)](/filings/0001628280-24-046969.md) | not reported | [0.38](/filings/0001628280-25-024649.md) | [(0.18)](/filings/0001628280-25-039531.md) | [(0.88)](/filings/0001628280-24-046969.md) | not reported | [(0.04)](/filings/0001628280-25-024649.md) | [(0.33)](/filings/0001628280-25-039531.md) | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.2](/filings/0001628280-24-046969.md) | [15.3](/filings/0001628280-26-022450.md) | [134](/filings/0001628280-25-024649.md) | [60.0](/filings/0001628280-25-039531.md) | [221](/filings/0001628280-25-051776.md) | [64.4](/filings/0001628280-26-022450.md) | [51.6](/filings/0001628280-26-033621.md) | [40.9](/filings/0001628280-26-055274.md) | [35.8](/filings/0001628280-25-051776.md) | [41.2](/filings/0001628280-26-055274.md) | [39.7](/filings/0001628280-26-033621.md) | [31.2](/filings/0001628280-26-055274.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [1,234](/filings/0001628280-23-038993.md) | [1,266](/filings/0001628280-25-013180.md) | [1,300](/filings/0001628280-24-022638.md) | [1,323](/filings/0001628280-24-036413.md) | [1,406](/filings/0001628280-24-046969.md) | [1,256](/filings/0001628280-26-022450.md) | [1,213](/filings/0001628280-25-024649.md) | [1,243](/filings/0001628280-25-039531.md) | [1,154](/filings/0001628280-25-051776.md) | [1,176](/filings/0001628280-26-055274.md) | [1,138](/filings/0001628280-26-033621.md) | [1,106](/filings/0001628280-26-055274.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [388](/filings/0001628280-23-038993.md) | [484](/filings/0001628280-25-013180.md) | [402](/filings/0001628280-24-022638.md) | [399](/filings/0001628280-24-036413.md) | [367](/filings/0001628280-24-046969.md) | [286](/filings/0001628280-26-022450.md) | [240](/filings/0001628280-25-024649.md) | [253](/filings/0001628280-25-039531.md) | [271](/filings/0001628280-25-051776.md) | [302](/filings/0001628280-26-055274.md) | [256](/filings/0001628280-26-033621.md) | [238](/filings/0001628280-26-055274.md) |
| Long-term debt | $m | [173](/filings/0001628280-23-038993.md) | [186](/filings/0001628280-25-013180.md) | [184](/filings/0001628280-24-022638.md) | [164](/filings/0001628280-24-036413.md) | [128](/filings/0001628280-24-046969.md) | [0.0](/filings/0001628280-26-022450.md) | not reported | [0.7](/filings/0001628280-25-039531.md) | [0.6](/filings/0001628280-25-051776.md) | [0.9](/filings/0001628280-26-055274.md) | [15.0](/filings/0001628280-26-033621.md) | [12.3](/filings/0001628280-26-055274.md) |
| Shareholders' equity | $m | [382](/filings/0001628280-23-038993.md) | [352](/filings/0001628280-25-013180.md) | [511](/filings/0001628280-24-022638.md) | [540](/filings/0001628280-24-036413.md) | [707](/filings/0001628280-24-046969.md) | [658](/filings/0001628280-26-022450.md) | [665](/filings/0001628280-25-024649.md) | [685](/filings/0001628280-25-039531.md) | [607](/filings/0001628280-25-051776.md) | [600](/filings/0001628280-26-055274.md) | [619](/filings/0001628280-26-033621.md) | [612](/filings/0001628280-26-055274.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: not reported
- Total assets: us-gaap:Assets
- Current liabilities: not reported
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.5) d](/filings/0001628280-24-046969.md) | [(0.7) d](/filings/0001628280-25-013180.md) | [(15.5)](/filings/0001628280-25-024649.md) | [(30.2) d](/filings/0001628280-25-039531.md) | [(4.9) d](/filings/0001628280-24-046969.md) | [(0.1) d](/filings/0001628280-25-013180.md) | [(30.2)](/filings/0001628280-25-024649.md) | [(19.9) d](/filings/0001628280-25-039531.md) | [(3.4) d](/filings/0001628280-25-051776.md) | [2.1 d](/filings/0001628280-26-022450.md) | [5.3](/filings/0001628280-26-033621.md) | [(2.4) d](/filings/0001628280-26-055274.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-046969.md) | [0.1 d](/filings/0001628280-26-022450.md) | [0.2](/filings/0001628280-25-024649.md) | [1.1 d](/filings/0001628280-25-039531.md) | [4.5 d](/filings/0001628280-25-051776.md) | [1.8 d](/filings/0001628280-26-022450.md) | [0.8](/filings/0001628280-26-033621.md) | [0.0 d](/filings/0001628280-26-055274.md) | [0.0 d](/filings/0001628280-25-051776.md) | [0.0 d](/filings/0001628280-26-022450.md) | [0.0](/filings/0001628280-26-033621.md) | [0.7 d](/filings/0001628280-26-055274.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001628280-25-024649.md) | not reported | not reported | not reported | [2.8](/filings/0001628280-26-033621.md) | [(2.8) d](/filings/0001628280-26-055274.md) | not reported | not reported | [5.7](/filings/0001628280-26-033621.md) | [0.0 d](/filings/0001628280-26-055274.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001628280-23-038993.md) | [57.5](/filings/0001628280-24-022638.md) | [114](/filings/0001628280-24-036413.md) | [63.6](/filings/0001628280-24-046969.md) | [121](/filings/0001628280-25-024649.md) | [71.7](/filings/0001628280-25-039531.md) | [86.4](/filings/0001628280-25-051776.md) | [147](/filings/0001628280-26-033621.md) | [99.9](/filings/0001628280-26-055274.md) | [102](/filings/0001628280-25-051776.md) | [111](/filings/0001628280-26-033621.md) | [111](/filings/0001628280-26-055274.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.